

## Focus

Development of novel therapeutics for the treatment of autoimmune diseases

## Technology

Soluble Fcγ-Receptors (sFcγRs)

## Products

SM101 for ITP  
SM101 for SLE  
SM101 for RA  
Anti-FcγRIIb monoclonal antibodies

## Management

Peter Buckel  
*Chief Executive Officer*  
Uwe Jacob  
*Corporate Development Officer*  
Peter Sondermann  
*Chief Scientific Officer*  
Sascha Tillmanns  
*Medical Director*  
Michael Kring\*  
*Chief Financial Officer*  
\* consulting

## Board

Thomas Hecht  
*Chairman*  
Ernst-Günter Afting  
Michael Motschmann  
Markus Hosang  
Ulrich Mahr

## Scientific Advisory Board

Robert Huber  
*Chairman*  
Fritz Melchers  
Zoltan Nagy  
Falk Nimmerjahn

## Key Shareholders

MIG AG  
BioMedInvest AG  
Santo Holding GmbH  
ZETACUBE s.r.l.  
KfW Mittelstandsbank  
Bayern Kapital GmbH  
Max-Planck-Gesellschaft e.V.  
Founders

## Contact details

SuppreMol GmbH  
Am Klopferspitz 19  
82152 Martinsried/München  
Germany  
Tel: +49 (0)89 30 90 50 680  
Fax: +49 (0)89 30 90 50 68 68  
Email: [info@suppremol.com](mailto:info@suppremol.com)  
Web: [www.suppremol.com](http://www.suppremol.com)

## Company Overview

SuppreMol GmbH is a privately held biotechnology company focusing on the development of novel therapeutics for autoimmune diseases. In particular, the Company specializes on the development of soluble Fcγ-Receptors (sFcγRs), which are recombinant autologous proteins with a proven strong immunosuppressive potential.

SuppreMol develops sFcγR as a therapeutic for autoimmune diseases, such as Idiopathic Thrombocytopenic Purpura, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. The Company also has an anti-FcγRIIb monoclonal antibody program to target FcγR receptors. The Company was founded in 2002 as a spin-off from the Max-Planck-Institute of Biochemistry and is located in Martinsried near Munich, Germany.

## Technology

SuppreMol develops soluble Fcγ-receptors (sFcγRs) for the treatment of autoimmune diseases. These sFcγRs compete with membrane bound Fcγ-receptors (FcγRs) on immune cells for the interaction with immune complexes. In this way they prevent the binding of these immune complexes to the cell. As a result, the feedback loop of autoantibody production, immune complex formation and restimulation of immune cells is inhibited. In consequence, inflammation, organ damage and additional immunological activation are prevented.

## Products

SuppreMol is developing soluble Fcγ-receptors (sFcγRs) for the treatment of autoimmune diseases such as Idiopathic Thrombocytopenic Purpura (ITP), Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA). The most advanced program is an sFcγR for use in ITP (SM101). SuppreMol will also develop this sFcγR for SLE and RA.

In addition, the Company has a program to target the FcγRIIb receptor by means of monoclonal antibodies.

## Pipeline Overview

	Lead Identification	Lead Optimization	Preclinic	Phase I
SM101 for ITP				
SM101 for SLE				
SM101 for RA				
mAb targeting FcγRIIb				
Next generation sFcR				

## Collaborations

SuppreMol evaluates the possibilities of in-licensing approaches complementary to the current projects to further increase the Company's development pipeline and intellectual property. SuppreMol is also looking for collaboration in the development of its product candidates, especially outside its first indication ITP.

## Investors

In May 2006, SuppreMol has closed a Series A financing round to fund product development of its lead product (SM101). Z-Cube, the venture capital subsidiary of the Zambon Group, provided €1.5M equity, KfW another €1.5M and Bayern Kapital €1.0M.

In 2008, SuppreMol closed a 15.7M Series B financing round with MIG AG, BioMedInvest, and Santo Holding as new investors. The Company's existing investors also participated in the round.